4.7 Article

Personalized prediction of depression in patients with newly diagnosed Parkinson's disease: A prospective cohort study

Journal

JOURNAL OF AFFECTIVE DISORDERS
Volume 268, Issue -, Pages 118-126

Publisher

ELSEVIER
DOI: 10.1016/j.jad.2020.02.046

Keywords

Depression; Machine learning; Parkinson's disease; Prediction model

Funding

  1. Key Technologies Research and Development Program [2017YFC1310300]
  2. National Natural Science Foundation of China [81673726]
  3. New Frontier Technology Project by Shanghai Shen Kang Hospital Development center [SHDC12018131]
  4. Michael J. Fox Foundation for Parkinson's Research
  5. Abbvie
  6. Allergan
  7. Avid Radiopharmaceuticals
  8. Biogen
  9. BioLegend
  10. Bristol-Myers Squibb
  11. Celgene
  12. Denali
  13. GE Healthcare
  14. Genentech
  15. GlaxoSmithKline
  16. Lilly
  17. Lundbeck
  18. Merck
  19. Meso Scale Discovery
  20. Pfizer
  21. Piramal
  22. Prevail Therapeutics
  23. Roche
  24. Sanofi Genzyme
  25. Servier
  26. Takeda
  27. Teva
  28. UCB
  29. Verily
  30. Voyager Therapeutics
  31. Golub Capital

Ask authors/readers for more resources

Background: Depressive disturbances in Parkinson's disease (dPD) have been identified as the most important determinant of quality of life in patients with Parkinson's disease (PD). Prediction models to triage patients at risk of depression early in the disease course are needed for prognosis and stratification of participants in clinical trials. Methods: One machine learning algorithm called extreme gradient boosting (XGBoost) and the logistic regression technique were applied for the prediction of clinically significant depression (defined as The 15-item Geriatric Depression Scale [GDS-15] >= 5) using a prospective cohort study of 312 drug-naive patients with newly diagnosed PD during 2-year follow-up from the Parkinson's Progression Markers Initiative (PPMI) database. Established models were assessed with out-of-sample validation and the whole sample was divided into training and testing samples by the ratio of 7:3. Results: Both XGBoost model and logistic regression model achieved good discrimination and calibration. 2 PD-specific factors (age at onset, duration) and 4 nonspecific factors (baseline GDS-15 score, State Trait Anxiety Inventory [STAI] score, Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire [RBDSQ] score, and history of depression) were identified as important predictors by two models. Limitations: Access to several variables was limited by database. Conclusions: In this longitudinal study, we developed promising tools to provide personalized estimates of depression in early PD and studied the relative contribution of PD-specific and nonspecific predictors, constituting a substantial addition to the current understanding of dPD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available